# EDGAR Filing Document

**Accession Number:** 0001166272
**File Stem:** 0001493152-23-007320
**Filing Date:** 2023-3
**Character Count:** 9282
**Document Hash:** 54411bbb497e410e28285b9994752508
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-007320.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001493152-23-007320

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENETIC TECHNOLOGIES LTD
- **CENTRAL INDEX KEY:** 0001166272
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51504
- **FILM NUMBER:** 23725584

**BUSINESS ADDRESS:**
- **STREET 1:** 60-66 HANOVER STREET
- **CITY:** FITZROY, VICTORIA
- **STATE:** C3
- **ZIP:** 3065
- **BUSINESS PHONE:** 011613-9415-1135

**MAIL ADDRESS:**
- **STREET 1:** 60-66 HANOVER STREET
- **CITY:** FITZROY, VICTORIA
- **STATE:** C3
- **ZIP:** 3065

**FORM 6-K**

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**dated March 13, 2023**

**Commission File Number 0-51504**

**GENETIC TECHNOLOGIES LIMITED**

(Exact Name as Specified in its Charter)

**N/A**

(Translation of Registrant's Name)

**60-66 Hanover Street**

**Fitzroy**

**Victoria 3065 Australia**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F **☒** Form 40-F **☐**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): **☐**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): **☐**

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes **☐** No **☒**

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: Macrh 13, 2023

---

| | |
|:---|:---|
| GENETIC TECHNOLOGIES LIMITED | GENETIC TECHNOLOGIES LIMITED |
| By: | /s/ *Tony Di Pietro* |
| Name: | Tony Di Pietro |
| Title: | Company Secretary |

---

EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit** | **Description of Exhibit** |
| 99.69 | [20230313 – Back-to-Back Studies Validate geneType Breast Cancer Risk Test FINAL](ex99-69.htm) |

---

## Exhibit 99.69

**Exhibit 99.69**

![](ex99-69_001.jpg)

**Back-to-back Studies Validate geneType Breast Cancer Risk Test**

**Melbourne, Australia, 13 March 2023:** Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal *Cancer Prevention Research.*

 

**Highlights:**

● 2<sup>nd</sup>
 published peer reviewed paper in the last month supporting the use of geneType, on the back of the ASX release dated February 9,
 2023.

● Utilised a prospective
 cohort of more than 200,000 women from the UK Biobank.

● geneType Breast Cancer
 Risk Assessment Test demonstrated improved performance compared to a gold-standard model (BCRAT) over a 5-year period.

● The study showed that geneType
 not only put more women into an increased risk category but also demonstrated women in this category developed breast cancer at a
 higher incidence.

The paper entitled: <u>Validation of an abridged breast cancer risk prediction model for the general population</u>, reports results from an extensive study undertaken by the GTG Scientific Team in collaboration with Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne.

This study is the third paper accepted for publication in the last six months that highlights the utility of the geneType Breast Cancer Risk Assessment Test as powerful risk stratification tool available to the general population. GeneType improved discrimination and risk categorization when compared to one of the most well-known models, the Breast Cancer Risk Assessment Tool (BRCAT). Over a five-year period, at-risk women classified ≥3% 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified ≥3% by BCRAT.

Dr Erika Spaeth, GTG's Director of Clinical & Medical Affairs, also lead author on the paper, noted "This publication highlights the potential utility of a risk stratification tool able to be used on the general population. There are a significant number of women that are identified as *at-increased risk* by geneType and these same women 'fly under the radar' if traditional clinical models are used".

GTG's CEO, Simon Morriss said, "This is *another* key milestone for the company highlighting our commitment to clinical and scientific validation of the geneType platform. The publication of this study in combination with the Nurses' Health Study, provides considerable evidence of utility for our discussions with US Payers and, importantly, in gaining additional traction to initiate a pilot study with one or more of these Payers".

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

Genetic Technologies Limited www.genetype.com info@gtglabs.com ABN 17 009 212 328 60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000

**Enquiries**

**Investor Relations**

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: <u>adrian.mulcahy@automicgroup.com.au</u>

**About Genetic Technologies Limited**

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit <u>www.genetype.com</u>

**Forward Looking Statements**

This announcement may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Genetic Technologies Limited www.genetype.com info@gtglabs.com ABN 17 009 212 328 60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000